Related Experiment Video
Updated: Dec 26, 2025

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Glucosamine Conjugated Gadolinium (III) Oxide Nanoparticles as a Novel Targeted Contrast Agent for Cancer Diagnosis
Mortezazadeh T1,2, Gholibegloo E3, Riyahi Alam N1
1PhD, Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, Iran.
Background:
Glucose transporter (Glut), a cellular transmembrane receptor, has a key role in the metabolism of cell glucose and is also associated with various human carcinomas.
Objective:
In this study, we evaluated a magnetic resonance (MR) imaging contrast agent for tumor detection based on paramagnetic gadolinium oxide (Gd2O3) coated polycyclodextrin (PCD) and modified with glucose (Gd2O3@PCD-Glu) for the targeting of overexpressed glucose receptors.
Material And Methods:
In this experimental study, 3T magnetic resonance imaging (MRI) scanner was used to assess the specific interactions between Glut1-overexpressing tumor cells (MDA-MB-231) and Gd2O3@PCD-Glu NPs. Furthermore, the capacity of transporting Gd2O3@PCD-Glu NPs to tumor cells was evaluated.
Results:
It was found that the acquired MRI T1 signal intensity of MDA-MB-231 cells that were treated with the Gd2O3@PCD-Glu NPs increased significantly. Based on the results obtained, Gd2O3@PCD-Glu NPs can be applied in targeting Glut1-overexpressing tumor cells in vivo, as well as an MRI-targeted tumor agent to enhance tumor diagnosis.
Conclusion:
Results have shown that glucose-shell of magnetic nanoparticles has a key role in diagnosing cancer cells of high metabolic activity.
More Related Videos
Related Concept Videos
Magnetic Resonance Imaging
Imaging Studies I: CT and MRI
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...

